Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
NCT05509400Phase 4Completed
- Sponsor
- Pfizer
- Start
- Oct 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 4, randomised, double-blind trial in migraine comparing Rimegepant with Placebo (2 arms). Primary endpoint: Percentage of Participants With Pain Relief. Started Oct 2022; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05509400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509400.